| FATE |
FATE THERAPEUTICS INC |
Common Stock, par value $0.001 per share |
15% |
$25,118,211 |
+$174,923 |
17,941,579 |
+0.7% |
Redmile Group, LLC |
02 Jul 2025 |
| ADCT |
ADC Therapeutics SA |
Common Shares, par value CHF 0.08 per share |
13% |
$57,966,905 |
|
15,666,731 |
0% |
Redmile Group, LLC |
31 Dec 2025 |
| SRRK |
Scholar Rock Holding Corporation |
Common Stock, par value $0.001 per share |
9.9% |
$323,935,513 |
|
9,885,124 |
|
Redmile Group, LLC |
31 Dec 2024 |
| ANNX |
Annexon, Inc. |
Common Stock, par value $0.001 per share |
9.9% |
$85,778,935 |
|
15,427,866 |
|
Redmile Group, LLC |
31 Dec 2025 |
| RGNX |
REGENXBIO Inc. |
Common Stock, par value $0.0001 per share |
9.9% |
$43,942,300 |
|
5,062,477 |
|
Redmile Group, LLC |
30 Jun 2025 |
| NGNE |
Neurogene Inc. |
Common Stock, $0.000001 par value |
9.9% |
$32,077,887 |
+$1,594,708 |
1,557,179 |
+5.2% |
Redmile Group, LLC |
31 Dec 2025 |
| RAPT |
RAPT Therapeutics, Inc. |
Common Stock, $0.0001 par value per share |
9.9% |
$14,934,463 |
|
1,765,303 |
|
Redmile Group, LLC |
30 Jun 2025 |
| RAPT |
RAPT Therapeutics, Inc. |
Common Stock, $0.0001 par value per share |
9.9% |
$12,121,231 |
|
13,932,449 |
|
Redmile Group, LLC |
31 Dec 2024 |
| ATRA |
Atara Biotherapeutics, Inc. |
Common Stock, par value $0.0001 per share |
9.9% |
$10,764,875 |
+$659,400 |
751,223 |
+6.5% |
Redmile Group, LLC |
12 Nov 2025 |
| STTK |
Shattuck Labs, Inc. |
Common Stock, par value $0.0001 per share |
9.9% |
$5,422,231 |
+$617,470 |
6,379,095 |
+13% |
Redmile Group, LLC |
25 Aug 2025 |
| ALXO |
ALX Oncology Holdings Inc. |
Common Stock, par value $0.001 per share |
8.5% |
$2,042,240 |
|
4,641,455 |
|
Redmile Group, LLC |
30 Jun 2025 |
| GRTS |
Gritstone bio, Inc. |
Common Stock, $0.0001 par value per share |
8.2% |
$131,635 |
|
13,163,457 |
|
Redmile Group, LLC |
31 Dec 2024 |
| STOK |
Stoke Therapeutics, Inc. |
Common Stock, $0.0001 par value per share |
8% |
$52,554,931 |
|
4,375,931 |
|
Redmile Group, LLC |
30 Jun 2025 |
| ABSI |
Absci Corporation |
Common Stock, $0.0001 par value per share |
6.5% |
$25,255,401 |
|
8,335,116 |
|
Redmile Group, LLC |
25 Apr 2025 |
| IMNM |
Immunome, Inc. |
Common Stock, $0.0001 par value per share |
5.2% |
$122,830,910 |
+$7,672,613 |
5,718,385 |
+6.7% |
Redmile Group, LLC |
31 Dec 2025 |
| ZYME |
Zymeworks Inc. |
Common Stock, par value $0.00001 per share |
4.9% |
$63,294,210 |
-$7,598,499 |
3,705,750 |
-11% |
Redmile Group, LLC |
30 Sep 2025 |
| PLRX |
Pliant Therapeutics, Inc. |
Common Stock, par value $0.0001 per share |
4.8% |
$4,545,900 |
|
2,895,478 |
|
Redmile Group, LLC |
31 Dec 2024 |
| SLN |
Silence Therapeutics plc |
Ordinary Shares, nominal value GBP 0.05 per share |
4.7% |
|
|
6,644,841 |
-7.7% |
Redmile Group, LLC |
31 Mar 2025 |
| FOLD |
Amicus Therapeutics, Inc. |
Common Stock, par value $0.01 per share |
4.6% |
$106,667,402 |
|
14,184,495 |
|
Redmile Group, LLC |
31 Dec 2024 |
| REPL |
Replimune Group, Inc. |
Common Stock, par value $0.001 per share |
0.7% |
$2,245,077 |
-$18,279,751 |
535,818 |
-89% |
Redmile Group, LLC |
30 Sep 2025 |
| IGMS |
IGM Biosciences, Inc. |
Common Stock, par value $0.01 per share |
0% |
$0 |
|
0 |
|
Redmile Group, LLC |
14 Aug 2025 |